title: Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study.
abstract: We analysed the effects of commonly used medications on human osteoblastic cell activity in vitro, specifically proliferation and tissue mineralisation. A list of medications was retrieved from the records of patients aged > 65 years filed in the database of the largest health maintenance organisation in our country (> two million members). Proliferation and mineralisation assays were performed on the following drugs: rosuvastatin (statin), metformin (antidiabetic), metoprolol (β-blocker), citalopram (selective serotonin reuptake inhibitor [SSRI]), and omeprazole (proton pump inhibitor (PPI)). All tested drugs significantly stimulated DNA synthesis to varying degrees, with rosuvastatin 5 µg/ml being the most effective among them (mean 225% (SD 20)), compared with metformin 10 µg/ml (185% (SD 10)), metoprolol 0.25 µg/ml (190% (SD 20)), citalopram 0.05 µg/ml (150% (sd 10)) and omeprazole 0.001 µg/ml (145% (SD 5)). Metformin and metoprolol (to a small extent) and rosuvastatin (to a much higher extent) inhibited cell mineralisation (85% (SD 5)). Our results indicate the need to evaluate the medications prescribed to patients in terms of their potential action on osteoblasts. Appropriate evaluation and prophylactic treatment (when necessary) might lower the incidence and costs associated with potential medication-induced osteoporosis.
authors.affiliation: Tel-Aviv Sourasky Medical Center, Division of Orthopedic Surgery, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: M
authors.initials: M
authors.lastname: Salai
authors.forename: D
authors.initials: D
authors.lastname: Somjen
authors.forename: R
authors.initials: R
authors.lastname: Gigi
authors.forename: O
authors.initials: O
authors.lastname: Yakobson
authors.forename: S
authors.initials: S
authors.lastname: Katzburg
authors.forename: O
authors.initials: O
authors.lastname: Dolkart
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000494:pharmacology*; D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology; D002113:Calcification, Physiologic / Q000187:drug effects*; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D015283:Citalopram / Q000494:pharmacology; D005464:Fluorobenzenes / Q000494:pharmacology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008687:Metformin / Q000494:pharmacology; D008790:Metoprolol / Q000494:pharmacology; D009853:Omeprazole / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects / Q000502:physiology; D054328:Proton Pump Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology; D000068718:Rosuvastatin Calcium; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D015283:Citalopram; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D008687:Metformin; D008790:Metoprolol; D009853:Omeprazole; D054328:Proton Pump Inhibitors; D011743:Pyrimidines; D000068718:Rosuvastatin Calcium; D017367:Selective Serotonin Reuptake Inhibitors; D013449:Sulfonamides
keywords: Bone cell; Fracture healing; Medication effects; Mineralisation; Osteoporosis